- Home
- NVAX vs NVCR Comparison
NVAX vs NVCR Comparison
Compare NVAX & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVAX
- NVCR
- Stock Information
- Founded
- NVAX 1987
- NVCR 2000
- Country
- NVAX United States
- NVCR Jersey
- Employees
- NVAX N/A
- NVCR N/A
- Industry
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- NVCR Medical/Dental Instruments
- Sector
- NVAX Health Care
- NVCR Health Care
- Exchange
- NVAX Nasdaq
- NVCR Nasdaq
- Market Cap
- NVAX 2.0B
- NVCR 1.8B
- IPO Year
- NVAX 1995
- NVCR 2015
- Fundamental
- Price
- NVAX $9.76
- NVCR $17.49
- Analyst Decision
- NVAX Buy
- NVCR Buy
- Analyst Count
- NVAX 6
- NVCR 5
- Target Price
- NVAX $17.83
- NVCR $26.60
- AVG Volume (30 Days)
- NVAX 7.2M
- NVCR 1.3M
- Earning Date
- NVAX 11-07-2024
- NVCR 10-30-2024
- Dividend Yield
- NVAX N/A
- NVCR N/A
- EPS Growth
- NVAX N/A
- NVCR N/A
- EPS
- NVAX N/A
- NVCR N/A
- Revenue
- NVAX $987,667,000.00
- NVCR $549,964,000.00
- Revenue This Year
- NVAX N/A
- NVCR $16.23
- Revenue Next Year
- NVAX N/A
- NVCR $6.09
- P/E Ratio
- NVAX N/A
- NVCR N/A
- Revenue Growth
- NVAX N/A
- NVCR 8.33
- 52 Week Low
- NVAX $3.53
- NVCR $10.87
- 52 Week High
- NVAX $23.86
- NVCR $24.74
- Technical
- Relative Strength Index (RSI)
- NVAX 36.20
- NVCR 43.24
- Support Level
- NVAX $9.52
- NVCR $15.61
- Resistance Level
- NVAX $10.63
- NVCR $17.31
- Average True Range (ATR)
- NVAX 0.57
- NVCR 1.29
- MACD
- NVAX -0.12
- NVCR 0.05
- Stochastic Oscillator
- NVAX 9.97
- NVCR 11.59
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.